slides · global inventory
Simon 2 Stage Design
Framework collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 9
Current window 1-9
Pages 1
Rows per page 30
Framework
1-9 of 9
04
The slide outlines a standard Simon 2-stage design, a common statistical framework in oncology trials to allow for early stopping for futility.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Product1 hit
15
The slide depicts a standard Simon 2-stage design, a common statistical framework for phase II oncology trials.Compass Therapeutics | Investor Presentation Deck | 20 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Market Size1 hit
09
Uses the Simon 2-Stage adaptive design framework.Compass Therapeutics | Investor Presentation Deck | 23 slides · Compass Therapeutics
Pitch deck Investor relations Beat · ProductLoop · Cost Of Inaction1 hit
15
The slide illustrates a standard Simon 2-Stage design, a common statistical framework for Phase II oncology trials.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
15
The slide illustrates a standard Simon 2-stage design, a common statistical framework for phase II oncology trials.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
26
The slide depicts a standard Simon 2-stage design, a common statistical framework in oncology clinical trials.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Beat · Market SizeLoop · Cost Of Inaction1 hit
26
The slide outlines a standard Simon 2-stage design where recruitment stops if the objective response rate (ORR) threshold is not met in the first stage.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
17
The trial met Simon 2-stage criteria but was discontinued to prioritize a study with Tagrisso.Genprex | Investor Presentation Deck | 58 slides · Genprex
Pitch deck Investor relations Beat · Satisfaction1 hit
29
Includes specific stopping rules for futility based on Disease Control Rate (DCR).Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 1 hit